ABT - Abbott Laboratories

NYSE - NYSE Delayed Price. Currency in USD
71.42
+0.90 (+1.28%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close70.52
Open70.99
Bid71.42 x 1200
Ask71.60 x 1800
Day's Range70.78 - 71.74
52 Week Range55.58 - 74.92
Volume8,317,029
Avg. Volume7,090,627
Market Cap125.437B
Beta (3Y Monthly)1.22
PE Ratio (TTM)143.70
EPS (TTM)0.50
Earnings DateJan 23, 2019
Forward Dividend & Yield1.28 (1.82%)
Ex-Dividend Date2019-01-14
1y Target Est79.47
Trade prices are not sourced from all markets
  • PR Newswire12 hours ago

    Abbott Offers a New Option for Physicians Treating Patients with Atrial Fibrillation

    ABBOTT PARK, Ill., Jan. 21, 2019 /PRNewswire/ -- Abbott (ABT) today announced U.S. Food and Drug Administration (FDA) approval of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, a new ablation catheter designed to help physicians accurately and effectively treat atrial fibrillation (AFib). The approval further expands Abbott's portfolio of cardiac ablation tools that integrate with the company's EnSite Precision™ cardiac mapping system to help physicians develop more precise images of the heart during cardiac ablation procedures.

  • CNBC3 days ago

    Cramer's game plan: This week, forecasts are more important than earnings

    CNBC's Jim Cramer looks ahead at a busy week of earnings reports that he says might drive investors crazy. Johnson & Johnson, Comcast and Starbucks will be among the companies issuing quarterly results. "I can't recall a time when the forecast will be more important, certainly much more important than the results," Cramer, host of "Mad Money," told viewers.

  • Cramer's game plan: This week, forecasts are more important than earnings
    CNBC3 days ago

    Cramer's game plan: This week, forecasts are more important than earnings

    Jim Cramer looks ahead at a busy week of earnings reports that he says might drive investors crazy.

  • Can Medical Devices Strength Drive Abbott (ABT) Q4 Earnings?
    Zacks3 days ago

    Can Medical Devices Strength Drive Abbott (ABT) Q4 Earnings?

    Abbott (ABT) Q4 results likely to show continued growth in Medical Devices business.

  • Is a Surprise Coming for Abbott (ABT) This Earnings Season?
    Zacks3 days ago

    Is a Surprise Coming for Abbott (ABT) This Earnings Season?

    Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • What Lies Ahead for Abbott (ABT) Stock This Earnings Season?
    Zacks4 days ago

    What Lies Ahead for Abbott (ABT) Stock This Earnings Season?

    Abbott (ABT) is showing a steady rise on a healthy growth graph within its Diabetes Care business for a considerable period.

  • PR Newswire4 days ago

    Japanese Red Cross Society Selects Abbott Technology to Screen Country's Blood and Plasma Supply

    ABBOTT PARK, Ill., Jan. 17, 2019 /PRNewswire/ -- Abbott (ABT) announced today that it has been selected by the Japanese Red Cross Society (JRC) to partner in screening the country's blood donations. The 8-year contract is for the exclusive supply of serological instrumentation, tests and consumables used for blood and plasma screening. The JRC screens approximately 5 million blood donations each year, helping ensure a safe supply of products needed for blood transfusions and plasma therapies.

  • 3 Weight-Loss Stocks in Focus on Rising Obesity Fears
    Zacks4 days ago

    3 Weight-Loss Stocks in Focus on Rising Obesity Fears

    Three companies with bright prospects as the U.S. weight-loss industry keeps up its battle against obesity.

  • MoneyShow5 days ago

    Top Picks 2019- Abbott Laboratories ABT

    If the 2018 market proved anything it is that you need to own stocks with an earnings backbone. That's because like the cream, great companies with strong earnings and strong products pipelines tend to quickly rise to the top. One such company is medical device maker Abbott Laboratories (ABT), suggests Jim Woods, editor of Fast Money Alert.

  • 3 Healthcare Stocks That Will Keep Your Portfolio Healthy
    InvestorPlace5 days ago

    3 Healthcare Stocks That Will Keep Your Portfolio Healthy

    Healthcare stocks cover a wide range of equities. Pharmaceuticals, equipment providers, insurers, pharmacies, technology, and even healthcare-related real estate investment trusts (REIT) can all fall under this category. However, these companies all benefit from the same trends. The share of healthcare in the overall U.S. economy continues to grow. The Centers for Medicare and Medicaid Services (CMS) estimates that healthcare encompasses about 17.9% of the U.S. economy. Moreover, with an estimated 10,000 baby boomers aging into Medicare a day, the pressure on limited healthcare resources continues to mount. * 7 Oversold Small-Cap Stocks With Massive Profit Growth While this can mean pain for the healthcare consumer, it can also bring benefit to those who invest in healthcare. With more of the baby boom generation on Medicare, a larger percentage of the population benefits from a healthcare subsidy. This gives a noticeable boost to healthcare stocks. Here are three that could help you benefit from this trend. InvestorPlace - Stock Market News, Stock Advice & Trading Tips ### AbbVie (ABBV) Source: Shutterstock Few healthcare stocks find themselves in a better position for both income and growth potential than AbbVie (NYSE:ABBV). Abbott Laboratories (NYSE:ABT) created AbbVie when it spun off its pharmaceutical division in 2013. After a growth spurt in 2017, ABBV fell as concerns about patent expirations on its blockbuster drug Humira weighed on the stock. Today it trades at about 30% below its 52-week high. However, ABBV stock also looks well-positioned to make a comeback. The Humira-driven swoon in ABBV has taken the forward P/E ratio to around 9.8. This comes in well below the average P/E of 18.2 over the last five years. Moreover, Evaluate Pharma ranks AbbVie's drug pipeline as second-best in the industry for value creation. Also, the company has time to transition to its next high-revenue drug. It will hold a patent on Humira in the U.S. until at least 2022. Analysts also do not seem worried as they predict profit growth of almost 10% per year through at least 2021. Furthermore, Wall Street considers AbbVie a dividend aristocrat due to its previous ties to Abbott. As a result, the company faces tremendous pressure to increase its dividend annually. AbbVie increased its payout from $3.59 per share to $4.28 per share this year. Hence, despite a generous yield of almost 4.9%, investors can probably expect annual increases in future years. Also, I see this massive dividend increase as a vote of confidence in itself. Couple that with the low P/E and the high ratings that AbbVie's drug pipeline has received, and ABBV should be one of the few healthcare stocks which will outperform in both the growth and income categories. ### Teladoc Health (TDOC) Source: MayApps207 via WikiMedia Buying Teladoc Health (NYSE:TDOC) amounts to buying into the future of healthcare. Without a doubt, the 17.9% of the economy that healthcare now consumes weighs heavily on family budgets. Teladoc allows patients to see a licensed doctor at any time via a PC or mobile device, reducing the need to take time off from work. It also saves money as visits can run as low as $40. Telehealth has only begun to realize its potential. Analysts estimate telehealth can handle about one-third of the 1.25 billion office visits that take place each year in the U.S. With Teladoc handling an estimated two million visits in 2018, the company still covers less than 1% of its potential market. Teladoc also shows that it can acquire the right partners to improve its quality and reach more patients. It widened its competitive moat by investing in diagnostic capabilities with a takeover of Best Doctors. It also partnered with CVS Health (NYSE:CVS) to provide care to its customers. Additionally, it boosted its offshore footprint by buying Advance Medical. Advance Medical was the leading telehealth provider outside the U.S. before TDOC purchased the company. Investors should note that TDOC remains expensive. Its price in the $55 per share range places it at around 9.3 times sales. Still, it has fallen almost 40% from its October high. Also, revenue grew by 78% in 2018. Although that growth will fall over time, analysts estimate that the company will turn profitable in 2021. * 10 Growth Stocks With the Future Written All Over Them Teladoc remains one of the more speculative healthcare stocks. However, with a $3.8 billion market cap, and a majority market share in a business that has reached less than one percent of its full potential, Teladoc could become one of the best stocks in healthcare. ### Dentsply Sirona (XRAY) Source: Shutterstock An aging population creates an increasing need for dental care and the equipment provided by Dentsply Sirona (NASDAQ:XRAY). As the ticker implies, Dentsply manufactures dental imaging equipment as well as consumable supplies and specialty dental products. Medicare rarely covers dental needs. However, many consumers place a high value on having a beautiful smile and the ability to chew food. Hence, most customers will spend money on services requiring XRAY's supplies and equipment. This also holds true outside of the U.S. Dentsply Sirona conducts business in over 120 countries. These other countries account for about 65% of the company's revenue. XRAY stock rose steadily between 2009 and 2018. However, in 2018, the stock lost almost half of its value. By late October, it traded as low as $33.93 per share, a level first seen in 2011. The stock sold off for most of the year on lower-than-expected sales. An impairment charge on goodwill and intangible assets in the second quarter hurt earnings. The stock fell by nearly 20% on August 7 following this announcement. However, management responded with a restructuring plan. While that breeds uncertainty, the forecasts indicate an opportunity for buyers. The forward P/E ratio stands at around 18, well below the five-year average of 28.1. Furthermore, analysts predict 11.2% consensus profit growth this year. They also foresee double-digit profit increases through at least 2021. XRAY faced a great deal of pain in 2018. Still, the need for dental supplies and equipment will only rise in the coming years. For this reason, the lower multiple and the predicted profit growth should bring about a recovery in Dentsply Sirona. As of this writing, Will Healy is long TDOC stock. You can follow Will on Twitter at @HealyWriting. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * Top 10 Global Stock Ideas for 2019 From RBC Capital * 10 A-Rated Stocks the Smart Money Is Piling Into * 5 Best Bank ETFs for This Week's Earnings Avalanche Compare Brokers The post 3 Healthcare Stocks That Will Keep Your Portfolio Healthy appeared first on InvestorPlace.

  • Abbott (ABT) Earnings Expected to Grow: Should You Buy?
    Zacks5 days ago

    Abbott (ABT) Earnings Expected to Grow: Should You Buy?

    Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • 10 Profit-Rich Stocks for Lean Times
    Investopedia5 days ago

    10 Profit-Rich Stocks for Lean Times

    Corporate profit margins are under pressure from a variety of forces, but these stocks are bucking the trend.

  • PR Newswire5 days ago

    Abbott To Acquire Cephea Valve Technologies, Inc.

    ABBOTT PARK, Ill., Jan. 16, 2019 /PRNewswire/ -- Abbott (ABT) announced today that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical device company developing a less-invasive heart valve replacement technology for people with mitral valve disease. Abbott provided capital and secured an option to purchase Cephea in 2015. Cephea's technology is being developed to provide an option for people whose diseased mitral valves need to be replaced.

  • 3 Top Diabetes Stocks to Watch in January
    Motley Fool6 days ago

    3 Top Diabetes Stocks to Watch in January

    Diabetes and related conditions affect over 100 million Americans and many more worldwide. Here are three companies helping fight that disease.

  • Investing.com6 days ago

    Abbott Labs Rises 3%

    Investing.com - Abbott Labs (NYSE:ABT) rose by 3.19% to trade at $70.45 by 15:09 (20:09 GMT) on Tuesday on the NYSE exchange.

  • Markit7 days ago

    See what the IHS Markit Score report has to say about Abbott Laboratories.

    # Abbott Laboratories ### NYSE:ABT View full report here! ## Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for ABT with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $13.93 billion over the last one-month into ETFs that hold ABT are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Negative The current level displays a negative indicator. ABT credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Abbott (ABT) Dips More Than Broader Markets: What You Should Know
    Zacks7 days ago

    Abbott (ABT) Dips More Than Broader Markets: What You Should Know

    In the latest trading session, Abbott (ABT) closed at $68.27, marking a -1.53% move from the previous day.

  • PR Newswire7 days ago

    FDA Approves World's First Device for Treatment of Premature Babies and Newborns with an Opening in Their Hearts (a Common Congenital Defect)

    ABBOTT PARK, Ill., Jan. 14, 2019 /PRNewswire/ -- Abbott (ABT) today announced the U.S. Food and Drug Administration (FDA) approved the Amplatzer Piccolo™ Occluder, the world's first medical device that can be implanted in the tiniest babies (weighing as little as two pounds) using a minimally invasive procedure to treat patent ductus arteriosus, or PDA. The Amplatzer Piccolo, a device even smaller than a small pea, now offers hope to premature infants and newborns who need corrective treatment, and who may be non-responsive to medical management and high risk to undergo corrective surgery.

  • Why This Group Is 'An Attractive Destination For Investors' In 2019
    Investor's Business Daily10 days ago

    Why This Group Is 'An Attractive Destination For Investors' In 2019

    Medical technology stalwarts Abbott Laboratories, Johnson & Johnson and Medtronic will likely face exchange-rate headwinds in 2019, an analyst said Friday. But he stayed bullish on medtech.

  • 3 Back-of-the-Shelf Consumer Stocks With Growth and Income
    InvestorPlace10 days ago

    3 Back-of-the-Shelf Consumer Stocks With Growth and Income

    Many tend to ignore consumer stocks not oriented toward the latest technology. Consumers and investors tend to focus on companies that produce new gadgets or bring the next wave of tech innovation. Many "boring" consumer stocks that have less of a tech focus, however, offer an impressive track record with dividends. This serves as an advantage over a tech industry, which tends to lag the S&P 500 when it comes to offering dividend stocks. Due in large part to dividends and a loyal customer base, consumer stocks tend to offer stability lacking in some of these more exciting stocks. Also, contrary to popular belief, many of these companies have become innovation leaders. Although the press may not always report it, these firms often pioneer new products that place them on the cutting edge in their industries. InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 A-Rated Stocks to Buy That The Smart Money Is Piling Into The following three companies lead this innovation. They also offer growth rates, valuations and dividend yields that should draw the attention of stock buyers. Source: Shutterstock ### AbbVie (ABBV) Admittedly, AbbVie (NYSE:ABBV) has made a few of my stock lists. I had hoped not to write about ABBV for that reason. However, when an equity offers an almost single-digit forward price-to-earnings (P/E) ratio, double-digit profit growth and the third-highest dividend yield among dividend aristocrats, I cannot leave it off in good conscience. ABBV stock trades a perfect storm for buyers. The patent on Humira faces patent expirations across the world. This has inspired a wave of selling in AbbVie. Despite this, analysts believe the company's drug pipeline will keep profits growing at double-digit rates. This has led to a forward PE ratio that stands at about 10.1. This perfect storm also applies to the firm's payouts. Due to its previous history as part of Abbott Laboratories (NYSE:ABT), ABBV holds dividend aristocrat status. When a stock hikes its payout for 46 years as AbbVie has, the stock price depends heavily on keeping this streak alive. Even better, ABBV has not made not offered a token hike in the payout merely to maintain the dividend aristocrat status. AbbVie went further, taking the payout from $2.56 per share in 2017 to $3.59 per share in 2018 to $4.28 per share this year. Approving such hikes when they face intense pressure to raise the payout every year shows a strong belief in its own future. Considering the low P/E ratio, the profit levels, and the dividend growth amounts, ABBV becomes one of the more obvious choices among consumer stocks. Source: Peyri Herrera via Flickr (Modified) ### Altria Group (MO) Few consumer stocks reflect resilience better than Altria (NYSE:MO). This year will mark 55 years since the U.S. Surgeon General released their report warning on the dangers of smoking. Amid anti-smoking campaigns, increasing tobacco taxes, and multi-billion dollar legal settlements, MO stock should have sunk into obscurity. Instead, Altria has become an unlikely success story. Despite the hostile environment for tobacco, the company continues to find opportunity. Currently, it invests in both smokeless tobacco and alcohol. It currently holds a 10.2% stake in Anheuser Busch-InBev (NYSE:BUD), for example. Also, despite legal barriers, it has also turned to the emerging marijuana sector. In late 2018, Altria purchased a 45% stake in Cronos (NASDAQ:CRON) for $1.8 billion. Even with the hostile business environment, MO stock manages to maintain a generous dividend. The current dividend of $3.20 per share yields almost 6.6%. Although MO does not hold dividend aristocrat status, the payout has increased in most years. As a result, MO stock has long remained a dividend powerhouse. Those who bought the equity in 2000 and reinvested the dividends receive their original investment back every year in dividends alone. The same holds true for those who bought in 1985 and spent or invested the payouts elsewhere. The company also looks attractive from a valuation and growth perspective. The forward P/E stands at 11.3. Moreover, analysts predict a 7.5% profit growth rate this year. Also, they expect those profit increases to remain in the high-single-digits for years to come. With its successes in related business, and its ability to maintain growth despite strong anti-tobacco sentiment, Altria should continue to stand out among consumer stocks. Source: Shutterstock ### General Mills (GIS) Despite producing recession-proof products, General Mills (NYSE:GIS) and its direct peers have endured years of struggle. An increasing interest in fresh and organic foods has diminished demand for the packaged foods General Mills has produced. As a result, it has seen both revenue and profits steadily fall over the last few years. This has taken GIS stock to levels first seen in 2012. However, a turnaround could occur soon. General Mills has begun to pivot to reflect consumer tastes. The company owns brands such as Cascadian Farm, Larabar, and Muir Glen that produce certified organic foods. Such products have helped revenues and profits turns around. After years of falling numbers, analysts predict a 5.5% increase in profits next year. Revenues have already begun to improve as Wall Street expects a 7.7% increase in sales growth for this year. Also, due to the years of decline, GIS stock trades at 12.7 forward earnings. Although this would not impress investors in a shrinking business, it begins to appear reasonable with growth returning. Also, with a five-year average P/E of 20.6, investors will likely enjoy a nice gain by waiting for the multiple to return to its long-term average. Even better for income-oriented investors, the $1.96 per share dividend yields around 4.75%. Since they have achieved a 15-year streak of dividend increases, another payout hike will likely come this year. Both consumers and investors have waited a long time for packaged food companies to embrace more natural foods. General Mills has finally made that move. With its attractive valuations and dividend yields, GIS stock should find a place among the more attractive high-dividend consumer stocks. As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks You Can Set and Forget (Even In This Market) * 10 Virtual Assistants for the Future of Smart Homes * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post 3 Back-of-the-Shelf Consumer Stocks With Growth and Income appeared first on InvestorPlace.

  • PR Newswire11 days ago

    Abbott and "Malaria No More" Work Together to End Malaria in Odisha, India

    - Abbott to supply rapid diagnostic tests critical for malaria detection and surveillance, technical expertise and funding support - Initiative focuses on Odisha, the state with the highest burden of malaria ...

  • Zacks Value Trader Highlights: PayPal, Abbott Labs, UnitedHealth, Lam Research and Visa
    Zacks11 days ago

    Zacks Value Trader Highlights: PayPal, Abbott Labs, UnitedHealth, Lam Research and Visa

    Zacks Value Trader Highlights: PayPal, Abbott Labs, UnitedHealth, Lam Research and Visa

  • Can We See Significant Institutional Ownership On The Abbott Laboratories (NYSE:ABT) Share Register?
    Simply Wall St.12 days ago

    Can We See Significant Institutional Ownership On The Abbott Laboratories (NYSE:ABT) Share Register?

    If you want to know who really controls Abbott Laboratories (NYSE:ABT), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders, Read More...

  • These 5 Companies are Earnings Perfection
    Zacks12 days ago

    These 5 Companies are Earnings Perfection

    Looking for only the best this earnings season? These companies haven't missed on earnings in the last 5 years.

  • Markit13 days ago

    See what the IHS Markit Score report has to say about Abbott Laboratories.

    # Abbott Laboratories ### NYSE:ABT View full report here! ## Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for ABT with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding ABT is favorable, with net inflows of $24.71 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Negative The current level displays a negative indicator. ABT credit default swap spreads are at their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.